Kolarov G, Orbetsova M, Nalbanski B, Kamenov Z, Georgiev S, Filipov E, Petrova Iu, Marinov B, Georgiev G
Akush Ginekol (Sofiia). 2001;42(2):37-41.
The use of nonhormonal drugs in order to ameliorate climacteric symptoms makes it possible to treat also those women in whom there are some contraindications or lack of compliance for taking hormonal replacement therapy. The drugs with complex effects on the whole body functions are more widely used recently. The aim of the present study is to assess the therapeutic effect of Cavinton (vinpocetin) on the degree of climacteric symptoms and to verify its complex beneficial influence. The study comprises of three groups of women in early menopause--control group (n = 30), treatment groups with normolipidaemia (n = 32) and with hyperlipidaemia (n = 29). All women presented with moderately expressed climacteric symptoms as assessed by Kupperman menopausal index and Hamilton-Anxiety-Skala (HAMA). The women in the 2nd and 3rd groups have been taking Cavinton in an oral dose of 5 mg three times daily for 3 months. The following parameters of lipid metabolism were determined in the beginning and at the end of the study: total, HDL- and LDL-cholesterol, triglycerides, and two indexes of lipid atherogenic risk--total/HDL-cholesterol ratio and atherogenic index (AI) = total--HDL/LDL-cholesterol. The menopausal complaints were assessed by Kupperman index and HAMA. Blood vessels reactivity was determined by pulsation index (PI). Statistically significant decrease in total cholesterol and LDL-cholesterol levels as well as amelioration of atherogenic indexes was observed in the 3rd group. Kupperman index and HAMA decreased significantly on the 45th day and the 3rd month in the women under treatment. No significant changes in PI were observed but a tendency towards a decrease was seen in the 3rd group. Our data suggest that Cavinton possesses complex beneficial effects in climacteric women significantly ameliorating climacteric symptoms as well as some parameters of lipid metabolism in women with hyperlipidaemia.
使用非激素药物来改善更年期症状，使得治疗那些存在激素替代疗法的某些禁忌症或不愿接受激素替代疗法的女性成为可能。近年来，对全身功能具有复合效应的药物得到了更广泛的应用。本研究的目的是评估卡文通（长春西汀）对更年期症状程度的治疗效果，并验证其复合有益影响。该研究包括三组处于绝经早期的女性——对照组（n = 30）、血脂正常组（n = 32）和高脂血症组（n = 29）。根据库珀曼绝经指数和汉密尔顿焦虑量表（HAMA）评估，所有女性均表现出中度的更年期症状。第2组和第3组的女性每天口服5毫克卡文通，每日三次，持续3个月。在研究开始和结束时测定了以下脂质代谢参数：总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、甘油三酯，以及两个脂质致动脉粥样硬化风险指标——总胆固醇/高密度脂蛋白胆固醇比值和致动脉粥样硬化指数（AI）=（总胆固醇 - 高密度脂蛋白胆固醇）/低密度脂蛋白胆固醇。通过库珀曼指数和HAMA评估更年期症状。通过搏动指数（PI）测定血管反应性。在第3组中观察到总胆固醇和低密度脂蛋白胆固醇水平有统计学意义的降低以及致动脉粥样硬化指数的改善。接受治疗的女性在第45天和第3个月时，库珀曼指数和HAMA显著下降。PI未观察到显著变化，但在第3组中可见下降趋势。我们的数据表明，卡文通对更年期女性具有复合有益作用，可显著改善更年期症状以及高脂血症女性的一些脂质代谢参数。
